Mustang Bio Inc (MBIO) Stock Price, Quote & News

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.mustangbio.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

BigMac_Sauce Jul. 18 at 2:41 PM

$MBIO time to bounce to pre market levels like it does every day! Lets goooo $SPY $QQQ $UNH

0 · Reply

Goldwave9 Jul. 18 at 2:01 PM

$MBIO All I care about is the buy zone. It can go up, down and sideways for all I care. Stay off those lower time frames and stop driving yourself crazy!!

1 · Reply

SMM82 Jul. 18 at 11:52 AM

$MBIO Recent MB-101 clinical trial edits. Interesting to see them recently update the collaborators to include BMY and Gateway. They have been using nivolumab and ipilimumab (BMY products) for the purposes of this trial, thus I'm not sure I can read too much into it. But still nice to see BMY get "more formally" attached to the trial. Piqued some of my attention. https://clinicaltrials.gov/study/NCT04003649?tab=history&a=20&b=21#version-content-panel

0 · Reply

StockMasterCash Jul. 18 at 11:38 AM

$MBIO is this live price? robinhood shows $2.40

0 · Reply

mikailoral Jul. 18 at 10:10 AM

$MBIO 2.47 letsgo %6

0 · Reply

2pumps1dump Jul. 18 at 8:57 AM

$MBIO will start adding slowly

0 · Reply

Stock_Catcher Jul. 18 at 2:54 AM

Money Friday Watchlist Pt.11 $MBIO $IMNN $APM $MIRA $COIN Let's Finish This Week STRONG team

0 · Reply

mak82 Jul. 17 at 8:10 PM

$MBIO they need to release marketing or partnership updates for new FDA approval medicine .ER wont work

0 · Reply

waeng Jul. 17 at 7:52 PM

$MBIO

0 · Reply

mikailoral Jul. 17 at 7:45 PM

$MBIO 2.27

0 · Reply

Dow Dips 1%; Mustang Bio Shares Spike Higher

Jul 7, 2025, 8:30 AM EDT - 11 days ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mar 5, 2025, 4:15 PM EST - 4 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Feb 27, 2025, 4:05 PM EST - 5 months ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 11, 2025, 4:10 PM EST - 5 months ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2025, 8:00 AM EST - 5 months ago

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 5 months ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Jan 14, 2025, 8:00 AM EST - 6 months ago

Mustang Bio Announces Reverse Stock Split

Nov 12, 2024, 8:30 AM EST - 8 months ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 7, 2024, 8:30 AM EST - 9 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Oct 24, 2024, 2:10 PM EDT - 9 months ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Jun 21, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2024, 2:52 AM EDT - 1 year ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 17, 2024, 9:21 AM EDT - 1 year ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

May 2, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 1 year ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 7, 2024, 7:30 AM EST - 1 year ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Jan 11, 2024, 8:30 AM EST - 1 year ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 11, 2023, 8:30 AM EST - 1 year ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:05 PM EST - 1 year ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:28 AM EDT - 1 year ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2023, 2:15 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 1 year ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 9:00 AM EDT - 1 year ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Sep 7, 2023, 8:15 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Jul 31, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jun 15, 2023, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

May 18, 2023, 8:03 AM EDT - 2 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 12, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 11, 2023, 4:03 PM EDT - 2 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mar 29, 2023, 4:15 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Jan 17, 2023, 8:15 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Dec 19, 2022, 8:30 AM EST - 2 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Nov 14, 2022, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 27, 2022, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Sep 23, 2022, 4:55 PM EDT - 3 years ago

Mustang Bio: This Horse May Gallop Still

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

BigMac_Sauce Jul. 18 at 2:41 PM

$MBIO time to bounce to pre market levels like it does every day! Lets goooo $SPY $QQQ $UNH

0 · Reply

Goldwave9 Jul. 18 at 2:01 PM

$MBIO All I care about is the buy zone. It can go up, down and sideways for all I care. Stay off those lower time frames and stop driving yourself crazy!!

1 · Reply

SMM82 Jul. 18 at 11:52 AM

0 · Reply

StockMasterCash Jul. 18 at 11:38 AM

$MBIO is this live price? robinhood shows $2.40

0 · Reply

mikailoral Jul. 18 at 10:10 AM

$MBIO 2.47 letsgo %6

0 · Reply

2pumps1dump Jul. 18 at 8:57 AM

$MBIO will start adding slowly

0 · Reply

Stock_Catcher Jul. 18 at 2:54 AM

Money Friday Watchlist Pt.11 $MBIO $IMNN $APM $MIRA $COIN Let's Finish This Week STRONG team

0 · Reply

mak82 Jul. 17 at 8:10 PM

$MBIO they need to release marketing or partnership updates for new FDA approval medicine .ER wont work

0 · Reply

waeng Jul. 17 at 7:52 PM

$MBIO

0 · Reply

mikailoral Jul. 17 at 7:45 PM

$MBIO 2.27

0 · Reply

BigMac_Sauce Jul. 17 at 6:09 PM

$MBIO after earnings. Gonna fly. $UNH $SPY $QQQ

1 · Reply

QuantNut Jul. 17 at 2:59 PM

$MBIO enjoy the bounce yall. In 2 hours MMs will bring it back to $2 or below.

2 · Reply

QuantNut Jul. 17 at 2:56 PM

$MBIO this is why you should be careful about clowns this 👇

1 · Reply

mikailoral Jul. 17 at 2:55 PM

$MBIO Interesting from 2 to 2.20

0 · Reply

mikailoral Jul. 17 at 2:31 PM

$MBIO where is the next drop location?

0 · Reply

Smithmark12 Jul. 17 at 2:21 PM

$MBIO Tough to know when to buy it just keeps going lower

0 · Reply

BuyHighSellLow4Life Jul. 17 at 2:01 PM

$MBIO okay wtf

0 · Reply

Smithmark12 Jul. 17 at 1:54 PM

$MBIO Way oversold now perfect time to buy back in

1 · Reply

SMM82 Jul. 17 at 1:37 PM

$MBIO Looks like this stock may be back to only knowing one direction for a while...

0 · Reply

Leezang Jul. 17 at 4:35 AM

$SBET – Noticing unusual volume spikes recently. Sports betting sector showing renewed strength. 🎯 Keeping this one on my radar at these levels. $BMGL – Blockchain/NFT sector name reacting well to market chatter. 🧠 Watching closely for signs of a technical bounce. $DFLI – EV space heating up again. Recent news triggered strong buying interest. ⚡ Oversold bounce setting up? $MITQ – Small-cap media/AI play getting attention again. 📺 Could gain more traction if sector momentum continues. $MBIO – Biotech with one of the most interesting setups right now. 💉 Renewed optimism around pipeline and potential catalysts.

1 · Reply

Goldwave9 Jul. 16 at 9:05 PM

$MBIO You will be happy by next Friday. I can't get any more specific than that.

1 · Reply

Deadpresidentz Jul. 16 at 8:45 PM

$GRI moving up under the radar here. Very similar to $MBIO

0 · Reply

Market Cap	10.46M
Revenue (ttm)	0.00
Net Income (ttm)	-15.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	850,300
Avg Vol	7,172,204
Day's Range	N/A - N/A
Shares Out	4.38M
Stochastic %K	6%
Beta	2.16
Analysts	Strong Buy
Price Target	$8.00